Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Sees Significant Increase in Short Interest

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 4,820,000 shares, an increase of 10.3% from the December 15th total of 4,370,000 shares. Based on an average trading volume of 476,100 shares, the short-interest ratio is currently 10.1 days. Currently, 13.5% of the company’s shares are short sold.

Insider Buying and Selling

In other news, EVP Yakob Liawatidewi sold 5,214 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the sale, the executive vice president now owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. This represents a 6.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO William J. Peters sold 7,426 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $386,523.30. Following the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $4,898,061.15. The trade was a 7.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,533 shares of company stock valued at $1,987,482. Corporate insiders own 27.10% of the company’s stock.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of AMPH. Aurora Investment Counsel increased its position in shares of Amphastar Pharmaceuticals by 0.4% during the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock worth $2,654,000 after purchasing an additional 232 shares in the last quarter. GAMMA Investing LLC grew its stake in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after buying an additional 273 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after buying an additional 301 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its stake in Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after buying an additional 398 shares during the last quarter. Finally, nVerses Capital LLC grew its holdings in shares of Amphastar Pharmaceuticals by 18.2% during the third quarter. nVerses Capital LLC now owns 2,600 shares of the company’s stock worth $126,000 after buying an additional 400 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on AMPH shares. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective for the company. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $60.33.

Amphastar Pharmaceuticals Stock Up 0.1 %

Shares of NASDAQ:AMPH opened at $35.70 on Friday. The firm has a 50 day simple moving average of $41.15 and a 200-day simple moving average of $44.04. Amphastar Pharmaceuticals has a twelve month low of $34.60 and a twelve month high of $56.88. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $1.72 billion, a PE ratio of 11.90, a P/E/G ratio of 1.12 and a beta of 0.82.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.